Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from ...

Moderna (NASDAQ: MRNA) extended gains for the seventh consecutive trading session, with the stock closing 2.14% higher at $29 ...

Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s ...

Moderna Inc. (NASDAQ:MRNA) is one of the high short interest stocks to buy right now. On November 20, Moderna announced that ...

Vinay Prasad, a top FDA official, blamed COVID shots for playing a role in the deaths of 10 children in a memo he sent to ...

Shares of Moderna, Inc. (NASDAQ:MRNA) are trading lower Monday following reports suggesting tighter controls on how vaccines gain approval.

The S&P 500 Healthcare sector (XLV) experienced a rise in average short interest during November, moving from 1.97% to 2.12%.

Moderna recently faced pressure after the U.S. Food and Drug Administration announced plans to require more rigorous safety ...

Moderna, Inc. is a biotechnology company specializing in the discovery and development of mRNA-based medicines. The company leverages its mRNA technology platform to address a broad range of diseases, ...